Klinisk och translationell melanomforskning – Hanna Erikssons forskargrupp

Article: ANNALS OF ONCOLOGY. 2023;34(4):420-430

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU

Article: BRITISH JOURNAL OF DERMATOLOGY. 2023;188(1):32-40

Association of metformin use and survival in patients with cutaneous melanoma and diabetes.

Krakowski I; Häbel H; Nielsen K; Ingvar C; Andersson TML; Girnita A; Smedby KE; Eriksson H

Article: NEOPLASIA. 2021;23(8):783-791

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.

Babačić H; Eriksson H; Pernemalm M

Article: ANNALS OF ONCOLOGY. 2021;32(6):766-777

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

Rawson RV; Adhikari C; Bierman C; Lo SN; Shklovskaya E; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Gonzalez M; Guminski AD; Tetzlaff MT; Stretch JR; Eriksson H; van Thienen JV; Wouters MW; Haanen JBAG; Klop WMC; Zuur CL; van Houdt WJ; Nieweg OE; Ch'ng S; Rizos H; Saw RPM; Spillane AJ; Wilmott JS; Blank CU; Long GV; van de Wiel BA; Scolyer RA

Article: NATURE MEDICINE. 2021;27(2):256-263

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU

Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.

Krakowski I; Bottai M; Häbel H; Masucci G; Girnita A; Smedby KE; Eriksson H

Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(14):1591-1601

Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Maurichi A; Miceli R; Eriksson H; Newton-Bishop J; Nsengimana J; Chan M; Hayes AJ; Heelan K; Adams D; Patuzzo R; Barretta F; Gallino G; Harwood C; Bergamaschi D; Bennett D; Lasithiotakis K; Ghiorzo P; Dalmasso B; Manganoni A; Consoli F; Mattavelli I; Barbieri C; Leva A; Cortinovis U; Espeli V; Mangas C; Quaglino P; Ribero S; Broganelli P; Pellacani G; Longo C; Del Forno C; Borgognoni L; Sestini S; Pimpinelli N; Fortunato S; Chiarugi A; Nardini P; Morittu E; Florita A; Cossa M; Valeri B; Milione M; Pruneri G; Zoras O; Anichini A; Mortarini R; Santinami M

Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(1):e000204

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.

Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H

Article: FRONTIERS IN ONCOLOGY. 2020;10:51

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.

Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtiö J; Mole DJ; Hansson J; Eriksson H; Tegnér J

Article: LANCET. 2019;394(10197):471-477

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.

Utjés D; Malmstedt J; Teras J; Drzewiecki K; Gullestad HP; Ingvar C; Eriksson H; Gillgren P

Article: LANCET ONCOLOGY. 2019;20(7):948-960

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU

Article: CANCER RESEARCH. 2018;78(20):5970-5979

Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.

Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J

Article: INTERNATIONAL JOURNAL OF CANCER. 2017;141(11):2243-2252

Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study.

Utjés D; Lyth J; Lapins J; Eriksson H

Article: JAMA DERMATOLOGY. 2015;151(4):410-416

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J

Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(13):1356-1364

Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J